GSA Capital Partners LLP Purchases Shares of 12,986 Royalty Pharma PLC $RPRX

GSA Capital Partners LLP acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,986 shares of the biopharmaceutical company’s stock, valued at approximately $458,000.

Other large investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. Financial Consulate Inc. acquired a new stake in Royalty Pharma in the third quarter valued at $35,000. Richardson Financial Services Inc. bought a new position in shares of Royalty Pharma in the 3rd quarter valued at about $54,000. Farther Finance Advisors LLC grew its position in shares of Royalty Pharma by 44.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 632 shares during the period. Finally, Fifth Third Bancorp increased its stake in shares of Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 362 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Buying and Selling

In related news, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Terrance P. Coyne sold 20,163 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $43.29, for a total value of $872,856.27. Following the sale, the chief financial officer directly owned 22,885 shares in the company, valued at $990,691.65. This represents a 46.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 965,020 shares of company stock valued at $38,670,657. 18.90% of the stock is owned by company insiders.

Royalty Pharma Stock Down 0.2%

RPRX opened at $45.40 on Wednesday. The stock has a fifty day moving average of $41.36 and a 200-day moving average of $38.68. The company has a market capitalization of $26.19 billion, a P/E ratio of 33.63 and a beta of 0.42. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $46.14. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The business had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. On average, equities analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be issued a dividend of $0.235 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s payout ratio is 69.63%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a research note on Thursday, February 12th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a research note on Thursday, December 11th. Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Friday, January 30th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $48.67.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.